Get the Stockscreener App
182.11
0.25%
-0.45
After Hours:
181.27
-0.84
-0.46%
Moderna Inc stock is traded at $182.11, with a volume of 17.67M.
It is down -0.25% in the last 24 hours and up +25.48% over the past month.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 35 mRNA development candidates in clinical studies as of August 2025. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
See More
Previous Close:
$182.56
Open:
$183.405
24h Volume:
17.67M
Relative Volume:
1.10
Market Cap:
$72.70B
Revenue:
$2.23B
Net Income/Loss:
$-3.19B
P/E Ratio:
-22.36
EPS:
-8.1462
Net Cash Flow:
$-1.60B
1W Performance:
+25.06%
1M Performance:
+25.48%
6M Performance:
+255.13%
1Y Performance:
+606.13%
1-Day Range:
$181.30
$192.31
1-Week Range:
$149.50
$192.31
52-Week Range:
$22.28
$192.31
Moderna Inc Stock (MRNA) Company Profile
Name
Moderna Inc
Sector
Industry
Phone
(617) 714-6500
Address
325 BINNEY STREET, CAMBRIDGE
Compare MRNA vs VRTX, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
MRNA
Moderna Inc
|
182.11 | 72.88B | 2.23B | -3.19B | -1.60B | -8.1462 |
VRTX
Vertex Pharmaceuticals Inc
|
516.34 | 130.53B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
801.82 | 82.77B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
945.82 | 60.30B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
365.00 | 41.64B | 5.76B | 514.49M | 1.10B | 4.4813 |
Moderna Inc Stock (MRNA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-28-26 | Resumed | Barclays | Equal Weight |
| Jan-07-26 | Resumed | UBS | Neutral |
| Dec-12-25 | Initiated | Jefferies | Hold |
| Mar-13-25 | Initiated | Citigroup | Neutral |
| Feb-18-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Jan-29-25 | Downgrade | Goldman | Buy → Neutral |
| Dec-18-24 | Downgrade | Argus | Buy → Hold |
| Dec-10-24 | Resumed | BofA Securities | Underperform |
| Nov-19-24 | Initiated | Berenberg | Hold |
| Nov-18-24 | Upgrade | HSBC Securities | Hold → Buy |
| Nov-15-24 | Initiated | Wolfe Research | Underperform |
| Oct-17-24 | Initiated | Bernstein | Mkt Perform |
| Sep-13-24 | Downgrade | JP Morgan | Neutral → Underweight |
| Sep-13-24 | Downgrade | Jefferies | Buy → Hold |
| Sep-13-24 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-28-24 | Upgrade | HSBC Securities | Reduce → Hold |
| Aug-07-24 | Upgrade | Deutsche Bank | Sell → Hold |
| Aug-05-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-26-24 | Downgrade | HSBC Securities | Hold → Reduce |
| Jan-02-24 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-29-23 | Initiated | Canaccord Genuity | Hold |
| Nov-03-23 | Upgrade | HSBC Securities | Reduce → Hold |
| Nov-02-23 | Downgrade | Deutsche Bank | Hold → Sell |
| Aug-04-23 | Downgrade | TD Cowen | Outperform → Market Perform |
| Aug-03-23 | Downgrade | Deutsche Bank | Buy → Hold |
| Jul-24-23 | Initiated | William Blair | Mkt Perform |
| Jul-14-23 | Initiated | HSBC Securities | Reduce |
| Jun-26-23 | Upgrade | UBS | Neutral → Buy |
| Apr-26-23 | Initiated | Guggenheim | Neutral |
| Mar-13-23 | Upgrade | TD Cowen | Market Perform → Outperform |
| Mar-02-23 | Initiated | RBC Capital Mkts | Outperform |
| Feb-24-23 | Downgrade | SVB Securities | Market Perform → Underperform |
| Dec-19-22 | Upgrade | Jefferies | Hold → Buy |
| Dec-14-22 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Oct-21-22 | Upgrade | SVB Leerink | Underperform → Mkt Perform |
| Sep-08-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Feb-01-22 | Upgrade | Redburn | Sell → Neutral |
| Jan-26-22 | Upgrade | Deutsche Bank | Sell → Hold |
| Jan-21-22 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-21-22 | Initiated | UBS | Neutral |
| Dec-07-21 | Initiated | Cowen | Market Perform |
| Nov-09-21 | Initiated | Wolfe Research | Outperform |
| Oct-22-21 | Initiated | Deutsche Bank | Sell |
| Oct-15-21 | Upgrade | Piper Sandler | Neutral → Overweight |
| Aug-06-21 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-21 | Downgrade | Piper Sandler | Overweight → Neutral |
| Jul-15-21 | Reiterated | Jefferies | Hold |
| Feb-01-21 | Downgrade | BofA Securities | Neutral → Underperform |
| Dec-16-20 | Downgrade | Jefferies | Buy → Hold |
| Dec-16-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Dec-09-20 | Downgrade | Needham | Buy → Hold |
| Nov-23-20 | Initiated | Wells Fargo | Equal Weight |
| Nov-17-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Sep-08-20 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jul-23-20 | Initiated | SVB Leerink | Mkt Perform |
| Jul-20-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-20 | Initiated | Jefferies | Buy |
| Jun-30-20 | Initiated | Argus | Buy |
| Jun-08-20 | Initiated | Barclays | Overweight |
| Apr-30-20 | Initiated | BMO Capital Markets | Outperform |
| Mar-05-20 | Downgrade | BofA/Merrill | Buy → Neutral |
| Dec-03-19 | Resumed | BofA/Merrill | Buy |
| Oct-25-19 | Initiated | ROTH Capital | Buy |
| Apr-05-19 | Initiated | Chardan Capital Markets | Buy |
View All
Moderna Inc Stock (MRNA) Latest News
Moderna Stock Hits a New High as CEO Says It’s More Than Covid Vaccines - Barron's
Healthcare Stocks Fall -- Healthcare Roundup - marketscreener.com
Moderna Eyes Cancer Vaccine Filing as It Expands Beyond COVID - Yahoo Finance
MRNA: Broad mRNA platform advances, led by oncology and rare disease innovation, drive future growth - TradingView
Moderna Stock Forecast: MRNA Hits $187 as Melanoma Vaccine Fuels Rally - FXLeaders
Moderna’s mRNA flu shot hits the target - Science News
Moderna stock rises 5.6 percent on melanoma data - AD HOC NEWS
Moderna stock gains 5.6 percent ahead of the open - AD HOC NEWS
Moderna stock gains 5.6 percent as melanoma data approaches - AD HOC NEWS
Moderna (MRNA) Co Founder Joined An AI Drug Discovery Company - simplywall.st
Moderna (NASDAQ:MRNA) Trading Up 5.6%What's Next? - MarketBeat
Moderna, Inc.'s stock price soars to $182.56, marking a robust 5.56% increase: A lucrative investment opportunity - Smartkarma
symbol__ Stock Quote Price and Forecast - CNN
Moderna stock gains 5.16 percent after the close - AD HOC NEWS
Moderna's Surge Faces Wall Street Skepticism as Analysts Question Cancer Vaccine Rally - finance.biggo.com
Was Moderna Stock's Cancer Vaccine Run Visible In Advance? - Yahoo Finance
Was Moderna Stock’s Cancer Vaccine Run Visible In Advance? - Trefis
Moderna Inc Stock (MRNA) Moved Up by 5.16% on Sep 22: A Full Analysis - TradingKey
Should You Buy Moderna Stock? Why Many Wall Street Analysts Say "No." - The Globe and Mail
Moderna Adds Another 5% and Is Up 500% in 2026. Can MRNA Stock Continue the Melt-Up? - Yahoo Finance
UBS reiterates Moderna stock rating ahead of melanoma data - Investing.com
How the Merck-Moderna mRNA melanoma vaccine is built per patient - qz.com
Top 3 Health Care Stocks That May Keep You Up At Night This Month - Benzinga
MRNA Hits 52-Week High: How Melanoma Study Results Keep Rally Going - Yahoo Finance
Moderna Says Sanofi Wants To 'Unjustly Profit' In Vax IP Suit - Law360
Moderna (MRNA) Stock Trades Up, Here Is Why - Yahoo Finance
Stocks in Demand: MRNA and SAMAIDEN Lead Investor Attentions - Moomoo
MRNA Looks 618.5% Overvalued on GF Value™ as Price-to-Sales Soars Amid Oncology Data - GuruFocus
Moderna rallies 12% to set new high (MRNA:NASDAQ) - Seeking Alpha
Moderna will reveal the data for its mRNA cancer vaccine next month. Here’s why it matters. - MarketWatch
Moderna (NASDAQ:MRNA) Sets New 12-Month HighHere's Why - MarketBeat
Moderna (MRNA) Soars to Fresh High Ahead of Pipeline Updates This Week - Yahoo Finance
Moderna Stock Surges As FDA Approval And Oncology Wins Fuel Rally - stockstotrade.com
Moderna Stock Jumps. Its mRNA Cancer Vaccine Is Getting Ready for Its Next Big Test. - Barron's
Moderna stock hits 52-week high at 176.75 USD - Investing.com
Moderna Inc Stock (MRNA) Moved Up by 14.21% on Sep 21: Drivers Behind the Movement - TradingKey
Alexandria proposes converting Moderna's former Cambridge headquarters into affordable housing - The Business Journals
Moderna To Present Additional Data From Key Melanoma Trial At ESMO Congress – Retail Says ‘Breakout Is Getting Hard To Ignore’ - Yahoo Finance
10 Health Care Stocks Whale Activity In Today’s Session - Benzinga
Moderna Stock Is Soaring: What's Going On? - Benzinga
Moderna Announces Late-Breaking Data to be Presented at ESMO Congress 2026 - Investing News Network
Biotech ETFs to Buy as Cancer Drug Breakthroughs Accelerate - Zacks Investment Research
Moderna Surges 9% as Phase 3 Melanoma Data Wins Presidential Symposium Slot; Merck and BioNTech Edge Higher - Yahoo Finance
Moderna Inc (MRNA): What a GF Score of 58 Says About the Stock - GuruFocus
MRNA Looks 600.2% Overvalued on GF Value™ - GuruFocus
Moderna presents cancer therapy data at ESMO congress - Investing.com
Moderna and Merck's experimental cancer therapy is set for three presentations - Stock Titan
Moderna Inc. stock gains on cancer vaccine progress and strong rally - AD HOC NEWS
Moderna, Inc. (MRNA) Stock Analysis: Navigating a -22.39% Potential Downside Amidst Biotech Innovation - DirectorsTalk Interviews
Moderna’s Bob Langer and AI pioneer Yann LeCun join board of Cellular Intelligence, bringing AI into medicine via a Parkinson’s drug - Yahoo Finance
Moderna, Inc. $MRNA Shares Acquired by Baird Financial Group Inc. - MarketBeat
Moderna Inc Stock (MRNA) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.26%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):